CoChat
Sign Up
Cited by 84Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting

Wallin, Åsa K., Andreasen, Niels, Eriksson, Sture, Båtsman, Stellan, Näsman, Birgitta, Ekdahl, Anne, Kilander, Lena, Grut, Mikaela +8 more·2007·Dementia and Geriatric Cognitive Disorders
DOI 10.1159/000098052
Open this paper in CoChat — free account

Abstract

BACKGROUND/AIMS: Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated. METHODS: The Swedish Alzheimer Treatment Study (SATS) is a descriptive, prospective, longitudinal, multicentre study. Four hundred and thirty-five outpatients with the clinical diagnosis of Alzheimer's disease, received treatment with donepezil. Patients were assessed with Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), global rating (CIBIC) and Instrumental Activities of Daily Living (IADL) at baseline and every 6 months for a total period of 3 years. RESULTS: The mean MMSE change from baseline was positive for more than 6 months and in subgroups of patients for 12 months. After 3 years of treatment the mean change from baseline in MMSE-score was 3.8 points (95% CI, 3.0-4.7) and the ADAS-cog rise was 8.2 points (95% CI, 6.4-10.1). This is better than expected in untreated historical cohorts, and better than the ADAS-cog rise calculated by the Stern equation (15.6 points; 95% CI, 14.5-16.6). After 3 years with 38% of the patients remaining, 30% of the them were unchanged or improved in the global assessment. CONCLUSION: Three-year donepezil treatment showed a positive global and cognitive outcome in the routine clinical setting.

Integrity signals

Registry

Crossref · 10.1159/000098052

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Longer term benefits of cholinesterase inhibitors, from 2 to 4 or more years, have been demonstrated in open-label extension and long-term prospective observational clinical cohort studies.

    “Longer term benefits, from 2 to 4 or more years have been demonstrated in open-label extension 69,[88][89][90] and long-term prospective observational clinical cohort studies.[91][92][93][94][95]”

    From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [93]

Cites

Flagged first, then by citations

1 of the 44 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Wallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., Jonsson, M., Olofsson, H., Londos, E., Wattmo, C., Eriksdotter Jönhagen, M., & Minthon, L.
Affiliations
  • Lund University (SE)
  • Karolinska University Hospital (SE)
  • Umeå University (SE)
  • Linköping University Hospital (SE)
  • Uppsala University (SE)
  • Danderyds sjukhus (SE)
  • Sahlgrenska University Hospital (SE)
  • Uddevalla sjukhus (SE)
ORCID
Venue
Dementia and Geriatric Cognitive Disorders
Publisher
S. Karger AG
Published
2006-12-18
Volume
23
Issue
3
Pages
150-160
ISSN
  • 1420-8008 (ISSN-L)
  • 1421-9824
DOI
10.1159/000098052
OpenAlex
W2005609961
Cited by
84
References
44
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 1 · 2015: 6 · 2014: 7 · 2013: 5 · 2012: 4
FWCI
5.32
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Dementia and Geriatric Cognitive Disorders (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
Keywords
donepezil, Alzheimer's disease, long-term treatment, cholinesterase inhibitors, cognitive decline, functional outcome, instrumental activities of daily living, real-world effectiveness
MeSH terms
Donepezil, Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Female, Humans, Indans, Longitudinal Studies, Male, Middle Aged, Neuropsychological Tests, Piperidines, Prospective Studies, Psychiatric Status Rating Scales, Sweden, Treatment Outcome, Disease Progression, Nootropic Agents, Statistics, Nonparametric

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review